Kangmei Zeng

HIF-1α inhibition promotes the efficacy of immune checkpoint blockade in the treatment of non-small cell lung cancer

Fan Luo, Feiteng Lu, Jiaxin Cao et al. · Cancer Letters · 2022 · 93 citations · Full text

Life Sciences, Immunology, Oncology +17

The BCL-2 inhibitor APG-2575 resets tumor-associated macrophages toward the M1 phenotype, promoting a favorable response to anti-PD-1 therapy via NLRP3 activation

Fan Luo, Han Li, Wenjuan Ma et al. · Cellular and Molecular Immunology · 2023 · 67 citations · Full text

Medicine, Immunology, Oncology +17

Gemcitabine and APG-1252, a novel small molecule inhibitor of BCL-2/BCL-XL, display a synergistic antitumor effect in nasopharyngeal carcinoma through the JAK-2/STAT3/MCL-1 signaling pathway

Fan Luo, Feiteng Lu, Miao‐Zhen Qiu et al. · Cell Death and Disease · 2021 · 31 citations · Full text

Medicine, Oncology, Pharmacology +15

Lymphocyte activating gene 3 protein expression in nasopharyngeal carcinoma is correlated with programmed cell death-1 and programmed cell death ligand-1, tumor-infiltrating lymphocytes

Fan Luo, Jiaxin Cao, Feiteng Lu et al. · Cancer Cell International · 2021 · 31 citations · Full text

Life Sciences, Immunology, Oncology +16

Predictive value of a reduction in the level of high-density lipoprotein-cholesterol in patients with non-small-cell lung cancer undergoing radical resection and adjuvant chemotherapy: a retrospective observational study

Fan Luo, Kangmei Zeng, Jiaxin Cao et al. · Lipids in Health and Disease · 2021 · 28 citations · Full text

Medicine, Oncology, Pharmacology +14